John A. Fling

Allergy and Immunology

855 Montgomery St
Fort Worth, TX 76107

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.

Journal: The Pediatric infectious disease journal

Published: May 15, 2020

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: August 23, 2018

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

Journal: The Pediatric infectious disease journal

Published: November 16, 2016

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

Journal: Vaccine

Published: November 30, 2012

Showing 1-4 of 4

Last Updated: 09/26/2026